XYLT2

Across TCGA pan-cancer cohorts, XYLT2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XYLT2 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher XYLT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XYLT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, OV, and UCEC are the cancer types where XYLT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.117	0.578	.002	24	view →
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
UCEC	OS	Median	All	1.000	0.864	.022	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

XYLT2–BRCA (OS)

Open the BRCA breakdown →